Sepracor Xopenex
Executive Summary
Abbott will co-promote levalbuterol. Sepracor currently markets the single-isomer form of the asthma drug albuterol using its own 65-person sales force and a 155-person contract sales force provided by Innovex (1"The Pink Sheet" Oct. 11, p. 23). Including Abbott, there are now over 500 reps supporting Xopenex, Sepracor said
You may also be interested in...
J&J Levaquin Review Could Affect Bristol's Positioning Of Tequin
The upcoming advisory committee review of a new indication for Ortho McNeil's Levaquin (levofloxacin) could affect Bristol-Myers Squibb's positioning of its pending quinolone antibiotic Tequin (gatifloxacin).
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials